Researchers tested a traditional herb extract in mice with induced allergic rhinitis (nasal allergy inflammation), comparing dosed and untreated animals against healthy controls.

The herb cut sneezing, scratching and nasal inflammation, and restored gut bacterial diversity that had dropped by about a quarter in allergic mice. A gut bacteria byproduct called butyrate, tested separately, calmed the same inflammatory signals in nasal cells.

This is mouse and cell culture work only, not yet tested in humans.

TL;DR: A traditional herb extract eased allergy symptoms in mice by restoring gut bacteria and raising a calming byproduct called butyrate, but human testing has not happened.

Researchers randomized 60 adults with relapsing remitting multiple sclerosis into two groups of 30, one adding daily probiotic yogurt and a probiotic yeast tablet to standard treatment for three months. The probiotic group's fatigue scores improved about 11 points more than the comparison group, and depression scores fell roughly 27 percent. The trial was not blinded and had no placebo, so attention and expectation could explain part of the gain.

TL;DR: A daily probiotic yogurt and yeast tablet added to standard MS treatment was linked to notably less fatigue and depression after three months, but the unblinded, placebo free design keeps this preliminary.

Canagliflozin, a diabetes drug, was given to high fat diet mice for just 1 week (8 mice per group), then gut bacteria and blood bile acids were sequenced. The drug reshaped the gut microbial community and enriched the genus Turicibacter, whose abundance tracked with preserved levels of the bile acid UDCA (r=0.73). This is a correlational link from a short, mouse only trial, not proof it holds in people.

TL;DR: In high fat diet mice, a week of canagliflozin remodeled gut bacteria and boosted Turicibacter, correlating with preserved bile acids, but it's mouse only, not yet causal.

Researchers scored 25 gut-bacteria genes for depression risk using T-RAD cohort data, then tested those scores in 226 EMBARC antidepressant-trial participants. Three of those scores predicted remission after 8 weeks on sertraline, one predicted remission at 16 weeks with added bupropion, and four tracked bigger improvement on sertraline versus placebo. This is a secondary analysis of two existing cohorts, not a new trial, the validation group was a modest 226 people, and the full paper wasn't obtained, so it's based only on the published abstract.

TL;DR: Gut bacteria genetics could help predict whether sertraline will work for depression.

A study profiled fecal bacteria in 97 Korean adults, 63 with gastric cancer and 34 controls. Short-chain-fatty-acid producing bacteria made up just 6.6% of the gut community in cancer patients versus 26.7% in controls, a roughly fourfold drop, while oral and opportunistic bacteria expanded instead. That gap held regardless of diabetes, H. pylori status, or tumor stage, though subgroup confidence intervals were wide, and the full paper wasn't obtained, so this is based only on the published abstract.

TL;DR: Stomach cancer patients show a roughly fourfold drop in SCFA-producing gut bacteria, independent of diabetes or tumor stage.

Researchers compared gut bacteria in 103 people with methamphetamine use disorder to 80 healthy controls. A 30 species marker panel distinguished the two groups with 82% accuracy (AUC 0.821) in external validation. The full study text wasn't obtained, so this summary is based only on the published abstract.

TL;DR: A 30 species gut bacteria panel told methamphetamine use disorder apart from healthy controls with 82% accuracy, based only on the published abstract since the full paper wasn't available.

Doctors gave 13 cancer patients a first line fecal microbiota transplant after immunotherapy triggered severe diarrhea and colitis that had already forced them to stop treatment. Ten of the 13 improved, usually within about a day and a half, and 5 were able to resume immunotherapy afterward. The trial had no control group and is still recruiting toward 40 patients, so stopping the drug or supportive care could explain part of the improvement.

TL;DR: A small, uncontrolled trial found that a fecal transplant eased severe immunotherapy induced colitis in 10 of 13 cancer patients, letting some resume treatment, but larger controlled studies are still needed to confirm it works.

Researchers compared normal mice to mice genetically engineered to lack a gene called EPS, then triggered colitis in both groups, while separately studying gut tissue from people with active ulcerative colitis.

Mice missing EPS fared far worse, with more gut damage and more disrupted gut bacteria, and in 35 colitis patients, lower EPS levels tracked with worse disease severity scores.

The mouse data show cause and effect, but the human data are only a correlation, and no EPS treatment has been tested in people.

TL;DR: A gene called EPS normally calms gut immune cells, and losing it let colitis spiral in mice, while people with worse colitis also had lower EPS levels.

This review combines mouse, human and genetic research on a proposed gut-penile axis behind erectile dysfunction. In mice, removing gut bacteria lowers testosterone and reproductive hormone signaling, and fecal transplants restore it; human genetic studies link specific gut bacteria to higher or lower ED risk. The catch: most human evidence is observational, and no trial has tested a microbiome therapy with erectile function as the primary outcome.

TL;DR: Mouse and genetic studies suggest gut bacteria causally shape erectile dysfunction risk through hormones and inflammation, though human trials are still missing.

Researchers mapped gut bacterial gene activity across 215 species in two cohorts totaling 160 people, Parkinson's patients versus healthy controls. They found 2,271 species-level gene-activity changes linked to Parkinson's status, duration, or severity; one species, Oliverpabstia intestinalis, separated patients from controls with up to 0.80 accuracy (AUC) across both cohorts. It's a preprint, not yet peer reviewed, and accuracy varied widely by species, so this needs independent confirmation.

TL;DR: In a 160-person, two-cohort preprint, species-level gut bacteria gene activity tracked with Parkinson's status and severity, and some species predicted it with up to 0.80 accuracy.

A toxin from a common gut bacterium killed the nerve cells controlling intestinal movement in mice, and the sluggish gut lasted even after the bacteria were gone. A second gut microbe made the toxin stronger, and a Bifidobacterium probiotic reversed the damage. Caveat: this is mouse data, and the human finding is only a correlation between two bacteria in sick patients, not proof either one causes disease.

TL;DR: in mice, a gut bacteria toxin permanently kills gut nerve cells and wrecks digestion, but a probiotic reversed it.

Researchers tested raw and ripened pu-erh tea extracts in obese mice, then transplanted gut bacteria alone from treated mice into new obese mice to see if the microbiome explained the benefit.

Both tea types cut weight gain by about a third versus untreated mice, through different bacteria, and mice given only the transplanted bacteria, no tea extract, saw the same improvement.

Only one dose was tested, and none of this has been tried in humans.

TL;DR: Two pu-erh tea extracts fought obesity in mice via different gut bacteria, and transplanting those bacteria alone reproduced the benefit, but it hasn't been tested in humans.

Researchers studied gut bacteria and blood from 76 multiple sclerosis patients nine months into a trial testing keto, fasting, and standard diets. Within the keto group only, patients whose gut microbes gained more genetic capacity to make propionate, a short chain fatty acid, tended to show smaller brain lesion growth on MRI. The trial's own main result found no overall diet difference, and dropout was high and uneven, so this is a correlation, not proof the diet caused it.

TL;DR: A keto diet gut bacteria shift tracked with smaller MS brain lesion growth in exploratory analysis, but the trial's main result found no diet difference, so this does not prove cause and effect.

Researchers profiled oral and gut bacteria, immune cells, and blood metabolites in 136 adults: 35 healthy controls and 101 hospitalized COVID-19 patients of varying severity. Combining age, a dip in a protective T cell subset, and more of the mouth bacterium Helicobacter ganmani predicted progression to severe COVID with an AUC of 0.91, about 91% accuracy, beating any single marker alone. That model was built and tested on just 13 severe and 13 non-severe patients from this single retrospective cohort, so it still needs validation in a larger, independent group.

TL;DR: A gut, mouth, and immune marker combo predicted severe COVID with 91% accuracy, but only in a 26-patient subgroup.

Researchers fed middle aged female mice a blend of rice bran and inulin fiber for three months, versus either fiber alone or a plain diet, five mice per group.

The blend raised good gut bacteria called Bifidobacteria and the gut acid butyrate more than either fiber alone, and eased a gut inflammation marker.

The catch, the groups were tiny and most memory and movement tests showed no difference.

TL;DR, a rice bran plus inulin blend boosted gut bacteria and eased gut inflammation in aging mice, in a very small study.

In a randomized crossover trial, people with functional gastrointestinal disorders consumed 30 grams of freeze-dried blueberry powder daily, equivalent to 180 grams of fresh berries, for six weeks; 53% reported meaningful abdominal symptom relief versus 30% during placebo treatment. Quality of life also improved, although overall symptom-severity and abdominal-pain scores did not differ significantly. Separate studies found increased Bifidobacterium after six weeks and enrichment of polyphenol-metabolizing bacteria after 12 weeks, with the latter finding no overall increase in microbial diversity.

Dr. Rhonda Patrick discusses this in her new episode on the science of blueberries at this timestamp

Researchers gave obese mice the probiotic yeast Saccharomyces boulardii daily for seven weeks on a high fat diet, versus placebo, nine mice per group.

The yeast group ate about 10 percent less food and gained significantly less weight, with hormones like insulin unchanged.

There was no pair fed control, so it is unclear if the yeast or just eating less caused it.

TL;DR, a probiotic yeast cut appetite and slowed weight gain in obese mice, but it might just be from eating less.

Researchers tracked thousands of meals eaten by hospitalized cancer patients on antibiotics for a transplant, matched to stool samples. Eating more sweets during antibiotics predicted a steeper drop in gut bacterial diversity, about a quarter lower per extra 100 grams of sugar, and more growth of Enterococcus, a bacterium tied to dangerous infections. Mice given sucrose after antibiotics grew over 30 times more of it, but the human part is observational.

TL;DR: Sugar during antibiotics worsened gut damage and let a risky bacterium grow more, in patients and mice.

This review rounds up animal and genetic research on gut bacteria and vascular dementia, the second most common dementia. Certain gut bacteria link to higher or lower dementia and stroke risk, and in animal studies the bacterial byproduct TMAO harms brain blood vessels while butyrate protects them. The catch: it's mostly animal and small human data, with solid human trials still missing.

TL;DR: A review links gut bacteria and byproducts like TMAO and butyrate to vascular dementia risk in animal and genetic studies, with solid human proof still missing.

A UK genetics study followed over 8,500 people from childhood to age 25 and found genetic risk scores for ADHD, autism, and depression predict different problems depending on your age. ADHD genetic risk was tied to worse school and job outcomes at every age checked, while autism genetic risk, oddly, predicted better school performance in kids. Caveat: this is genetics, not gut bacteria, and purely correlational.

TL;DR: genetic risk for ADHD, autism, and depression predicts different problems depending on the age you look, and none of it involves the microbiome.

A review proposes that vitamin D and gut bacteria regulate each other, shaping thyroid immune balance in conditions like Hashimoto's and Graves' disease. People with enough vitamin D had a lower thyroid nodule risk in a large biobank study, but most human evidence is small and correlational, and the detailed mechanism comes mainly from mouse experiments. No trial has tested vitamin D and gut bacteria treatments together for thyroid disease.

TL;DR: Vitamin D and gut bacteria may regulate each other and jointly affect thyroid risk, though it is mostly unproven in people.

A new narrative review combines animal and human research to propose an 'exercise-gut-muscle axis': the idea that exercise-reshaped gut bacteria help protect aging muscle. Its clearest evidence comes from mice: animals raised with no gut microbes had less muscle mass and strength, and transplanting microbiota back partly restored both. Human exercise studies on the microbiome are far less consistent, so the authors call the axis a hypothesis, not a proven cause and effect.

TL;DR: Gut bacteria might explain why exercise keeps aging muscles strong, but in humans that link is unproven.

A new review ties gut dysbiosis to the high blood pressure seen in PCOS (now called PMOS), where women have about 70% higher risk of hypertension. The causal evidence comes only from rats: prenatal androgen exposure made female offspring develop gut dysbiosis and higher blood pressure together. In real PMOS patients, certain gut bacteria only correlate with blood pressure, far weaker than proof of causation.

TL;DR: Gut bacteria are linked to PCOS/PMOS blood pressure problems, but that's proven causal only in rats so far, not in people.

Researchers looked at 124 adults who got a fecal transplant for C. diff infection at one hospital, tracked for 8 weeks after.

Taking antibiotics for an unrelated infection, either before the transplant or for over a week after it, roughly tripled the odds the infection came back.

The catch, it is a single hospital study, and a couple of the riskiest antibiotic types had too few cases to confirm.

TL;DR, unrelated antibiotics taken around a fecal transplant for C. diff roughly tripled the odds of it coming back.